208 related articles for article (PubMed ID: 34183772)
1. DNAJA1 promotes cancer metastasis through interaction with mutant p53.
Kaida A; Yamamoto S; Parrales A; Young ED; Ranjan A; Alalem MA; Morita KI; Oikawa Y; Harada H; Ikeda T; Thomas SM; Diaz FJ; Iwakuma T
Oncogene; 2021 Aug; 40(31):5013-5025. PubMed ID: 34183772
[TBL] [Abstract][Full Text] [Related]
2. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
[TBL] [Abstract][Full Text] [Related]
3. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.
Parrales A; Ranjan A; Iyer SV; Padhye S; Weir SJ; Roy A; Iwakuma T
Nat Cell Biol; 2016 Nov; 18(11):1233-1243. PubMed ID: 27775703
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 Depletion by Novel Inhibitors for HSP40/J-Domain Proteins Derived from the Natural Compound Plumbagin.
Alalem M; Bhosale M; Ranjan A; Yamamoto S; Kaida A; Nishikawa S; Parrales A; Farooki S; Anant S; Padhye S; Iwakuma T
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077724
[TBL] [Abstract][Full Text] [Related]
5. DNAJA1- and conformational mutant p53-dependent inhibition of cancer cell migration by a novel compound identified through a virtual screen.
Nishikawa S; Kaida A; Parrales A; Ranjan A; Alalem M; Ren H; Schoenen FJ; Johnson DK; Iwakuma T
Cell Death Discov; 2022 Oct; 8(1):437. PubMed ID: 36316326
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53.
Xu D; Tong X; Sun L; Li H; Jones RD; Liao J; Yang GY
Mol Carcinog; 2019 Nov; 58(11):2052-2064. PubMed ID: 31397499
[TBL] [Abstract][Full Text] [Related]
7. DNAJA1 promotes proliferation and metastasis of breast cancer by activating mutant P53/NF-κB pathway.
Wu J; Yang Q; Zhu Y; Xia T; Yi L; Wang J; Ren X
Pathol Res Pract; 2023 Dec; 252():154921. PubMed ID: 37977037
[TBL] [Abstract][Full Text] [Related]
8. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
9. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
[TBL] [Abstract][Full Text] [Related]
11. Regulation of p53 and Cancer Signaling by Heat Shock Protein 40/J-Domain Protein Family Members.
Kaida A; Iwakuma T
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948322
[TBL] [Abstract][Full Text] [Related]
12. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.
Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M
Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412
[TBL] [Abstract][Full Text] [Related]
14. The interplay between mutant p53 and the mevalonate pathway.
Parrales A; Thoenen E; Iwakuma T
Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070
[TBL] [Abstract][Full Text] [Related]
15. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14.
Du Y; Liu Z; You L; Hou P; Ren X; Jiao T; Zhao W; Li Z; Shu H; Liu C; Zhao Y
Cancer Res; 2017 May; 77(10):2661-2673. PubMed ID: 28280038
[TBL] [Abstract][Full Text] [Related]
17. Druggable sites/pockets of the p53-DNAJA1 protein-protein interaction: In silico modeling and in vitro/in vivo validation.
Jacobsen D; Bushara O; Mishra RK; Sun L; Liao J; Yang GY
Methods Enzymol; 2022; 675():83-107. PubMed ID: 36220282
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion.
Zhang S; Wang C; Ma B; Xu M; Xu S; Liu J; Tian Y; Fu Y; Luo Y
Cell Rep; 2020 Jul; 32(1):107879. PubMed ID: 32640214
[TBL] [Abstract][Full Text] [Related]
19. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.
Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W
Elife; 2015 Aug; 4():. PubMed ID: 26271008
[TBL] [Abstract][Full Text] [Related]
20. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]